MCID: FNC006
MIFTS: 35

Functional Gastric Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Functional Gastric Disease

MalaCards integrated aliases for Functional Gastric Disease:

Name: Functional Gastric Disease 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:1159
ICD9CM 35 536.8
UMLS 69 C0013396

Summaries for Functional Gastric Disease

MalaCards based summary : Functional Gastric Disease is related to enamel erosion and tricuspid valve stenosis. An important gene associated with Functional Gastric Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Ion channel transport. The drugs Histamine and Mianserin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and testes, and related phenotypes are Decreased viability and behavior/neurological

Related Diseases for Functional Gastric Disease

Diseases related to Functional Gastric Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Related Disease Score Top Affiliating Genes
1 enamel erosion 10.7 ATP4A SST
2 tricuspid valve stenosis 10.7 ATP4A CCK
3 chronic tympanitis 10.7 CCK TRPV1
4 cryptogenic organizing pneumonia 10.6 ATP4A TRPV1
5 rhabdomyosarcoma 10.6 ATP4A HRH2
6 lacrimal apparatus disease 10.6 ATP4A HRH2
7 angelucci's syndrome 10.6 ATP4A SST
8 scrotal carcinoma 10.6 ATP4A HRH2
9 ornithosis 10.5 CCK HTR3A
10 survival motor neuron spinal muscular atrophy 10.5 GHRL SST TRPV1
11 chondroma 10.5 CCK SST TRPV1
12 scrotum melanoma 10.4 ATP12A ATP4A
13 congenital aphakia 10.4 ATP12A ATP4A
14 thrombophilia 10.4 GHRL GHSR SST
15 urethral calculus 10.4 ATP12A ATP4A
16 breast ductal adenoma 10.4 ATP12A ATP4A
17 hypopituitarism 10.4 ATP12A ATP4A
18 chagas disease 10.4 CCK GHRL HTR3A
19 amyotrophic lateral sclerosis type 5 10.4 ATP12A ATP4A
20 anodontia 10.4 HTR3A PDE5A
21 atheroembolism of kidney 10.4 ATP12A ATP4A
22 microphthalmia, syndromic 12 10.4 ATP12A ATP4A
23 synostosis 10.4 ATP12A ATP4A
24 conjunctival degeneration 10.4 HTR7 PDE5A
25 muscle cancer 10.4 ATP12A ATP4A
26 polysyndactyly with cardiac malformation 10.4 ATP12A ATP4A
27 focal hand dystonia 10.4 ATP12A ATP4A
28 cloacal exstrophy 10.4 ATP12A ATP4A
29 semantic agnosia 10.3 CCK HTR7 TRPV1
30 cervical adenosarcoma 10.3 CCK HTR7 TRPV1
31 iris mixed cell melanoma 10.3 CCK HRH2 SST
32 thrombocytopenia due to platelet alloimmunization 10.3 ATP12A ATP4A
33 proliferative fasciitis 10.3 ATP12A ATP4A
34 retinal vascular occlusion 10.3 CCK HRH2 SST
35 early-onset parkinson disease 10.3 GHRL SST
36 typhoid fever 10.3 CCK HTR3A SST
37 spinocerebellar ataxia 18 10.3 ATP12A ATP4A
38 cushing's syndrome 10.3 ATP4A CCK PTGS2
39 cervicitis 10.3 CCK PTGS2 TRPV1
40 hyperimmunoglobulin syndrome 10.2 HTR3A HTR7
41 fungal gastritis 10.2 ATP12A ATP4A
42 carcinoma of unknown primary site, childhood 10.2 HTR3A SST
43 cubitus valgus with mental retardation and unusual facies 10.2 ATP12A ATP4A
44 primary syphilis 10.2 ATP12A ATP4A SST
45 bone giant cell sarcoma 10.2 ATP12A ATP4A SST
46 brain ependymoma 10.2 ATP4A HRH2 PTGS2
47 ileocolitis 10.1 ATP12A ATP4A
48 hodgkin's paragranuloma 10.1 ATP12A ATP4A SPAG7
49 albinism, oculocutaneous, type v 10.1 HTR3A HTR7 TRPV1
50 pervasive developmental disorder 10.1 CCK GHRL HTR7 TRPV1

Graphical network of the top 20 diseases related to Functional Gastric Disease:



Diseases related to Functional Gastric Disease

Symptoms & Phenotypes for Functional Gastric Disease

GenomeRNAi Phenotypes related to Functional Gastric Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 GHSR HRH2 HTR3A MLN
2 Decreased viability GR00381-A-2 9.28 GHSR
3 Decreased viability GR00381-A-3 9.28 GHSR HRH2 HTR3A MLN

MGI Mouse Phenotypes related to Functional Gastric Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 CCK GHRL GHSR HRH2 HTR3A HTR7
2 digestive/alimentary MP:0005381 9.5 ATP12A ATP4A GHRL GHSR HRH2 PTGS2
3 homeostasis/metabolism MP:0005376 9.36 HTR3A HTR7 PTGS2 SST TRPV1 ATP12A

Drugs & Therapeutics for Functional Gastric Disease

Drugs for Functional Gastric Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 75614-87-8, 51-45-6 774
2
Mianserin Approved Phase 4 24219-97-4 4184
3
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
4
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 161796-78-7, 119141-88-7 4594 9579578
5
Liraglutide Approved Phase 4,Phase 2,Phase 3 204656-20-2 44147092
6
Ticagrelor Approved Phase 4 274693-27-5 9871419
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
8
Clarithromycin Approved Phase 4 81103-11-9 84029
9
Dexlansoprazole Approved Phase 4,Early Phase 1 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4,Early Phase 1 103577-45-3 3883
11
Metronidazole Approved Phase 4 443-48-1 4173
12
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
13
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Furazolidone Approved, Vet_approved Phase 4 67-45-8 3435 5323714
16
Potassium Citrate Approved, Vet_approved Phase 4
17
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
23
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
24
Rabeprazole Approved, Investigational Phase 4,Phase 2 117976-89-3 5029
25
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
26
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
29
Trimebutine Approved Phase 4 39133-31-8
30
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
31
Calcium acetate Approved Phase 4 62-54-4
32
Sevelamer Approved Phase 4 52757-95-6, 152751-57-0 3085017
33 Orange Approved, Nutraceutical Phase 4
34
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
35 Licorice Approved, Nutraceutical Phase 4
36 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
37 Mosapride Investigational Phase 4 112885-41-3
38
Maleic acid Experimental Phase 4 110-16-7 444266
39 Adrenergic Agents Phase 4,Phase 2,Phase 3
40 Adrenergic alpha-Antagonists Phase 4
41 Adrenergic Antagonists Phase 4
42 Antidepressive Agents Phase 4,Phase 2,Phase 3
43 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
44 Antidepressive Agents, Tricyclic Phase 4,Phase 2,Phase 3
45 Histamine Antagonists Phase 4,Phase 2,Phase 3
46 Histamine H1 Antagonists Phase 4
47
Histamine Phosphate Phase 4,Phase 2,Phase 3 51-74-1 65513
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Psychotropic Drugs Phase 4,Phase 3,Phase 2
50
Serotonin Phase 4,Phase 2,Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 405)

id Name Status NCT ID Phase Drugs
1 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4 Mirtazapine
2 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
3 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
4 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
5 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
6 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
7 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
8 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Unknown status NCT01592279 Phase 4 liraglutide;Insulin injections
9 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
10 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
11 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
12 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
13 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
14 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
15 CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity Completed NCT01748643 Phase 4 deep neuromuscular blockade with rocuronium, reversal with sugammadex;normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine
16 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
17 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
18 Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
19 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
20 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
21 The Muscle Relaxation-study Completed NCT01523886 Phase 4 Rocuronium;Rocuronium
22 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
23 Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) Recruiting NCT02390973 Phase 4
24 BRAVO Study for Functional Dyspepsia Recruiting NCT01349413 Phase 4 Esomeprazole 20mg
25 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
26 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
27 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Active, not recruiting NCT01882088 Phase 4 Mucofalk
28 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
29 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Active, not recruiting NCT02206256 Phase 4 Omega-3 fatty acid capsules
30 Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia Not yet recruiting NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
31 Once Weekly GLP-1 in Persons With Spinal Cord Injury Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
32 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4 Placebo;Pantoprazole + Placebo
33 Lansoprazole for Subgroups of Functional Dyspepsia Terminated NCT01040455 Phase 4 Lansoprazole;placebo
34 Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 Terminated NCT01277497 Phase 4 Sevelamer carbonate;Calcium acetate
35 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
36 Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome Withdrawn NCT00673972 Phase 4
37 Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate Withdrawn NCT02090348 Phase 4 dimethyl fumarate
38 Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition Unknown status NCT01052896 Phase 3 Gabapentin;Placebo
39 Role of Routine Nasogastric Decompression After Subtotal Gastrectomy Unknown status NCT00164918 Phase 3
40 Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy Unknown status NCT01344135 Phase 3
41 Early Alimentation Following Colorectal Surgery Unknown status NCT00290524 Phase 3
42 Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis Unknown status NCT00506337 Phase 2, Phase 3 Qingyi granules
43 Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor Unknown status NCT01048463 Phase 3 Nutriall;LDEPA;Placebo;HDEPA;Chemotherapy
44 Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1% Unknown status NCT02068859 Phase 3 Diclofenac Cream 8%;Diclofenac Gel 1%
45 Functional Dyspepsia Treatment Trial Completed NCT00248651 Phase 2, Phase 3 Amitriptyline;Escitalopram;Placebo
46 Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia Completed NCT03225248 Phase 3 UI05MSP015CT;Gasmotin
47 Itopride in Functional Dyspepsia:a Dose Finding Study Completed NCT00272103 Phase 2, Phase 3 Itopride (drug)
48 Acupuncture for Patients With Function Dyspepsia Completed NCT01671670 Phase 2, Phase 3
49 Rifaximin for Functional Dyspepsia Completed NCT01643083 Phase 2, Phase 3 Rifaximin;Placebo
50 To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Completed NCT00761358 Phase 3 Z-338;Placebo

Search NIH Clinical Center for Functional Gastric Disease

Genetic Tests for Functional Gastric Disease

Anatomical Context for Functional Gastric Disease

MalaCards organs/tissues related to Functional Gastric Disease:

39
Liver, Lung, Testes, Kidney, Colon, Bone, Breast

Publications for Functional Gastric Disease

Variations for Functional Gastric Disease

Expression for Functional Gastric Disease

Search GEO for disease gene expression data for Functional Gastric Disease.

Pathways for Functional Gastric Disease

GO Terms for Functional Gastric Disease

Cellular components related to Functional Gastric Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.92 CCK HTR3A SST TRPV1

Biological processes related to Functional Gastric Disease according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.81 ATP12A ATP4A HTR3A TRPV1
2 excitatory postsynaptic potential GO:0060079 9.61 GHRL HTR3A TRPV1
3 negative regulation of insulin secretion GO:0046676 9.58 GHRL GHSR
4 hormone-mediated signaling pathway GO:0009755 9.57 GHRL GHSR
5 actin polymerization or depolymerization GO:0008154 9.55 GHRL GHSR
6 cellular response to ATP GO:0071318 9.54 PTGS2 TRPV1
7 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.52 ATP12A ATP4A
8 G-protein coupled receptor signaling pathway GO:0007186 9.5 GHRL GHSR HRH2 HTR7 MLN MLNR
9 adult feeding behavior GO:0008343 9.49 GHRL GHSR
10 negative regulation of interleukin-1 beta production GO:0032691 9.48 GHRL GHSR
11 growth hormone secretion GO:0030252 9.4 GHRL GHSR
12 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.37 GHRL GHSR
13 response to organonitrogen compound GO:0010243 9.33 PTGS2 SST TRPV1
14 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.32 GHRL GHSR
15 positive regulation of appetite GO:0032100 9.26 GHRL GHSR
16 negative regulation of appetite GO:0032099 9.16 CCK
17 decidualization GO:0046697 8.8 GHRL GHSR PTGS2
18 signal transduction GO:0007165 10.03 CCK GHSR HRH2 HTR7 MLNR PDE5A

Molecular functions related to Functional Gastric Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.32 HTR3A HTR7
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP12A ATP4A
3 growth hormone-releasing hormone receptor activity GO:0016520 9.16 GHSR MLNR
4 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A
5 hormone activity GO:0005179 8.92 CCK GHRL MLN SST

Sources for Functional Gastric Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....